Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
Abstract Introduction Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT1A receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bioequivalence (BE) between tablet and capsule formulations of ulotar...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-03-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40120-023-00459-8 |
| _version_ | 1797822636739264512 |
|---|---|
| author | Yu-Luan Chen Hironobu Tsukada Snezana Milanovic Lei Shi Yan Li Yongcai Mao Kenneth S. Koblan Gerald R. Galluppi |
| author_facet | Yu-Luan Chen Hironobu Tsukada Snezana Milanovic Lei Shi Yan Li Yongcai Mao Kenneth S. Koblan Gerald R. Galluppi |
| author_sort | Yu-Luan Chen |
| collection | DOAJ |
| description | Abstract Introduction Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT1A receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bioequivalence (BE) between tablet and capsule formulations of ulotaront and the food effect (FE) on pharmacokinetics (PK) of tablet form in healthy adult human subjects. Methods The BE study applied an open-label two-period crossover design in 24 healthy volunteers. Subjects were randomly assigned (1:1) to dosing sequence AB or BA (A, 25 mg ulotaront tablet; B, 25 mg ulotaront capsule). The FE study also used an open-label randomized two-period crossover design in 20 healthy volunteers. Subjects were fasted overnight then randomly assigned (1:1) to dosing sequence AB or BA (A, fasted condition; B, fed condition). Dosing periods were separated by 1 week for both studies. Serial plasma samples from each period were collected and analyzed by LC–MS/MS. PK parameters were calculated using Phoenix WinNonlin® software. Results For the BE study, geometric mean ulotaront C max values were 93.28 and 86.98 ng/mL for tablet and capsule, respectively. C max ratio was 107.25% (90% CI 101.84–112.94%). Geometric mean ulotaront area under the plasma concentration–time curve from time 0 to infinity (AUC0–∞) values were 868.8 and 829.3 ng·h/mL for tablet and capsule, respectively. AUC0–∞ ratio was 104.76% (90% CI 100.68109.01%). For the FE study, geometric mean ulotaront C max was 157.89 and 157.95 ng/mL under fed and fasted conditions, respectively. Geometric mean ratio of C max was 99.96% (90% CI 94.48–105.77%). Geometric mean ulotaront AUC0–∞ was 1584.2 ng·h/mL fed and 1589.2 ng·h/mL fasted. Geometric mean ratio for AUC0–∞ was 99.69% (90% CI 95.02–104.58%). There was a delay in t max (median difference 1.47 h) in the fed condition. Conclusions The results showed geometric mean ratios and 90% CIs for both C max and AUC0–∞ for ulotaront were well within typical bioequivalence criteria of 80–125% for both the BE and FE studies, thereby confirming the bioequivalence of the two dosage forms and no significant food effect. |
| first_indexed | 2024-03-13T10:12:02Z |
| format | Article |
| id | doaj.art-e6aa69b4bb0544e5afb9f1d477d9b8a5 |
| institution | Directory Open Access Journal |
| issn | 2193-8253 2193-6536 |
| language | English |
| last_indexed | 2024-03-13T10:12:02Z |
| publishDate | 2023-03-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Neurology and Therapy |
| spelling | doaj.art-e6aa69b4bb0544e5afb9f1d477d9b8a52023-05-21T11:30:41ZengAdis, Springer HealthcareNeurology and Therapy2193-82532193-65362023-03-0112381583210.1007/s40120-023-00459-8Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in HumansYu-Luan Chen0Hironobu Tsukada1Snezana Milanovic2Lei Shi3Yan Li4Yongcai Mao5Kenneth S. Koblan6Gerald R. Galluppi7Sunovion Pharmaceuticals Inc.Sunovion Pharmaceuticals Inc.Sunovion Pharmaceuticals Inc.Sunovion Pharmaceuticals Inc.Sunovion Pharmaceuticals Inc.Sunovion Pharmaceuticals Inc.Sunovion Pharmaceuticals Inc.Sunovion Pharmaceuticals Inc.Abstract Introduction Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT1A receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bioequivalence (BE) between tablet and capsule formulations of ulotaront and the food effect (FE) on pharmacokinetics (PK) of tablet form in healthy adult human subjects. Methods The BE study applied an open-label two-period crossover design in 24 healthy volunteers. Subjects were randomly assigned (1:1) to dosing sequence AB or BA (A, 25 mg ulotaront tablet; B, 25 mg ulotaront capsule). The FE study also used an open-label randomized two-period crossover design in 20 healthy volunteers. Subjects were fasted overnight then randomly assigned (1:1) to dosing sequence AB or BA (A, fasted condition; B, fed condition). Dosing periods were separated by 1 week for both studies. Serial plasma samples from each period were collected and analyzed by LC–MS/MS. PK parameters were calculated using Phoenix WinNonlin® software. Results For the BE study, geometric mean ulotaront C max values were 93.28 and 86.98 ng/mL for tablet and capsule, respectively. C max ratio was 107.25% (90% CI 101.84–112.94%). Geometric mean ulotaront area under the plasma concentration–time curve from time 0 to infinity (AUC0–∞) values were 868.8 and 829.3 ng·h/mL for tablet and capsule, respectively. AUC0–∞ ratio was 104.76% (90% CI 100.68109.01%). For the FE study, geometric mean ulotaront C max was 157.89 and 157.95 ng/mL under fed and fasted conditions, respectively. Geometric mean ratio of C max was 99.96% (90% CI 94.48–105.77%). Geometric mean ulotaront AUC0–∞ was 1584.2 ng·h/mL fed and 1589.2 ng·h/mL fasted. Geometric mean ratio for AUC0–∞ was 99.69% (90% CI 95.02–104.58%). There was a delay in t max (median difference 1.47 h) in the fed condition. Conclusions The results showed geometric mean ratios and 90% CIs for both C max and AUC0–∞ for ulotaront were well within typical bioequivalence criteria of 80–125% for both the BE and FE studies, thereby confirming the bioequivalence of the two dosage forms and no significant food effect.https://doi.org/10.1007/s40120-023-00459-8Ulotaront (SEP-363856)Comparative bioequivalenceFood effectN-Desmethyl metaboliteLC–MS/MSPharmacokinetics |
| spellingShingle | Yu-Luan Chen Hironobu Tsukada Snezana Milanovic Lei Shi Yan Li Yongcai Mao Kenneth S. Koblan Gerald R. Galluppi Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans Neurology and Therapy Ulotaront (SEP-363856) Comparative bioequivalence Food effect N-Desmethyl metabolite LC–MS/MS Pharmacokinetics |
| title | Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans |
| title_full | Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans |
| title_fullStr | Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans |
| title_full_unstemmed | Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans |
| title_short | Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans |
| title_sort | comparative bioequivalence of tablet and capsule formulations of ulotaront and the effect of food on the pharmacokinetics of the tablet form in humans |
| topic | Ulotaront (SEP-363856) Comparative bioequivalence Food effect N-Desmethyl metabolite LC–MS/MS Pharmacokinetics |
| url | https://doi.org/10.1007/s40120-023-00459-8 |
| work_keys_str_mv | AT yuluanchen comparativebioequivalenceoftabletandcapsuleformulationsofulotarontandtheeffectoffoodonthepharmacokineticsofthetabletforminhumans AT hironobutsukada comparativebioequivalenceoftabletandcapsuleformulationsofulotarontandtheeffectoffoodonthepharmacokineticsofthetabletforminhumans AT snezanamilanovic comparativebioequivalenceoftabletandcapsuleformulationsofulotarontandtheeffectoffoodonthepharmacokineticsofthetabletforminhumans AT leishi comparativebioequivalenceoftabletandcapsuleformulationsofulotarontandtheeffectoffoodonthepharmacokineticsofthetabletforminhumans AT yanli comparativebioequivalenceoftabletandcapsuleformulationsofulotarontandtheeffectoffoodonthepharmacokineticsofthetabletforminhumans AT yongcaimao comparativebioequivalenceoftabletandcapsuleformulationsofulotarontandtheeffectoffoodonthepharmacokineticsofthetabletforminhumans AT kennethskoblan comparativebioequivalenceoftabletandcapsuleformulationsofulotarontandtheeffectoffoodonthepharmacokineticsofthetabletforminhumans AT geraldrgalluppi comparativebioequivalenceoftabletandcapsuleformulationsofulotarontandtheeffectoffoodonthepharmacokineticsofthetabletforminhumans |